2 Result: Immunovant
BlackRock Posts Mixed Q3 Earnings; Bullish View On Immunovant
October 13th, 2023
BlackRock, Inc. (NYSE: BLK), an investment management and financial services company, reported third-quarter 2023 adjusted earnings per share (EPS) of $10.91, surpassing the consensus EPS estimate of $8.26. However, the company's revenue for the peri. Read more
Immunovant's IMVT-1402 Data Sparks Momentum; Ferguson Outperforms Estimates
September 26th, 2023
Shares of Immunovant, Inc. (Nasdaq: IMVT) surged by more than 40% in pre-market trading after promising Phase 1 trial results for IMVT-1402. Administered subcutaneously in healthy adults, IMVT-1402 demonstrated significant dose-dependent reductions i. Read more
Want To Find Some News?
News By Industries
Recent Post
-
December 05th, 2025
FDA Approves Nerve Scaffold for the Treatment of Sensory Nerve Discontinuity
December 04th, 2025December 02nd, 2025Earnings Countdown: Salesforce, Snowflake, and Guidewire Take Center Stage
November 30th, 2025Wall Street Eyes CrowdStrike, Marvell Technology, and GitLab as Earnings Near
November 30th, 2025
Member Login